BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31817456)

  • 1. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.
    Sun H; Zhuo L; Dong H; Huang W; She N
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31817456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
    Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
    Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
    Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
    Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
    Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
    Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
    Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
    Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient Arylation of 2,7-Naphthyridin-1(2
    Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W
    ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
    Qi H; Chen L; Liu B; Wang X; Long L; Liu D
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations.
    Elrazaz EZ; Serya RAT; Ismail NSM; Albohy A; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2021 Aug; 113():105019. PubMed ID: 34091286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel tricyclic pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors.
    Abdel Aziz YM; Said MM; El Shihawy HA; Abouzid KA
    Bioorg Chem; 2015 Jun; 60():1-12. PubMed ID: 25899678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors.
    Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
    Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
    Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors.
    Jiao Y; Huang F; Xu P; Zhang Y; Yang S; Zhang D; Lu T; Tang W
    Med Chem; 2016; 12(4):328-37. PubMed ID: 26667231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
    Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.